SecBot SecBot
424B5 ·Filed Aug 11, 2026

ABCL

AbCellera Biologics Inc.
BEARISH
Impact 7/10
Horizonimmediate Processed3mo ago SEC0001193125-26-344944
Notable filing: 424B5
Actionable Insight ▼ Bearish

The $200M dilutive offering is a clear negative signal for near-term price action, likely overwhelming the positive ABCL635 Phase 2 data. Traders should expect downward pressure on ABCL shares as the market absorbs the new supply. Monitor the final offering price and the stock's reaction post-pricing; the 60-day lock-up on insiders may provide a temporary floor, but the overhang from the offering is significant.

DirectionBearish
Confidencehigh
Horizonimmediate

Drugs in focus

ABCL drug pipeline →

ABCL635

● Neutral Named in this 424B5
Impact
Phase
Phase 2
Time to market
Phase 3 is planned to begin in 2027. Assuming a multi-year Phase 3 program followed by FDA review, potential approval would likely be 2029-2030 at the earliest, barring accelerated development.
Next catalyst
None dated

What to watchThe next major catalyst for ABCL635 is the planned Phase 3 start in 2027, which the company confirmed on its Q3 2026 earnings call. Positive Phase 2 data (83% vs 33% placebo reduction in hot flash frequency) has already been reported, so the stock's next binary event is likely years away. Watch for FDA feedback on Phase 3 trial design and any partnership/licensing deals that could validate the asset's value.

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$10.36
T+0 close · Aug 11, 2026 · via day close
Latest settled
+7.48%
T+60 · $11.13
Vs SPY
+12.60%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 12 $10.36entry
  2. T+1 · 3mo ago +5.94%α +5.24% · $10.97
  3. T+5 · 3mo ago +15.98%α +16.43% · $12.01
  4. T+20 · 2mo ago +1.01%α +2.91% · $10.46
  5. T+60 · 12d ago +7.48%α +12.60% · $11.13
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

AbCellera Biologics Inc. filed a preliminary prospectus supplement for a $200 million underwritten public offering of common shares and pre-funded warrants. The offering follows positive Phase 2 data for its lead drug candidate, ABCL635, announced on August 10, 2026. The dilutive capital raise, coming on the heels of a positive catalyst, signals a need for cash to fund clinical development and will significantly dilute existing shareholders at a ~$9.32 reference price, creating a bearish near-term dynamic despite the positive clinical news.

Key Facts

  • AbCellera is offering $200,000,000 of common shares and pre-funded warrants.
  • The offering is priced at an undisclosed amount; the last reported sale price on August 10, 2026 was $9.32 per share.
  • Net tangible book value as of June 30, 2026 was $811.7 million, or $2.65 per share, implying substantial dilution for new investors.
  • Proceeds will fund continued R&D and clinical advancement of the internal pipeline, including lead program ABCL635.
  • Positive Phase 2 top-line results for ABCL635 were announced on August 10, 2026, showing statistically significant reductions in VMS frequency and severity.
  • The company had 306,469,632 common shares outstanding as of June 30, 2026.
  • Underwriters include Jefferies, J.P. Morgan, Cantor, UBS, and BMO Capital Markets.
  • Executive officers, directors, and certain shareholders are subject to a 60-day lock-up agreement.

Financial Impact

$200,000,000 offering of common shares and pre-funded warrants; net proceeds to be determined after underwriting discounts and expenses. Historical net tangible book value was $2.65 per share as of June 30, 2026, indicating significant dilution.

dilutionshare countcash and marketable securities

Risk Factors

  • Immediate and substantial dilution to existing shareholders.
  • Potential for further stock price decline as the market absorbs the new shares.
  • Broad discretion over use of proceeds may not enhance shareholder value.
  • No established trading market for the pre-funded warrants, limiting liquidity for those instruments.
  • Sales of a substantial number of shares after the lock-up period could pressure the stock.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
93% bullish (15 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
424B5 Filing (Primary)0001193125-26-344944
Document: 0001193125-26-344944-index-headers.html0001193125-26-344944
Document: 0001193125-26-344944-index.html0001193125-26-344944
Document: 0001193125-26-344944.txt0001193125-26-344944

Track record

16 reports on ABCL

Performance horizon

6 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +127.09% at T+20 after the Jul 29, 2026 report. 7 of 9 went positive at some point.

Filters
  1. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $11.63 Now $11.12 −4.39% settles Feb 12
  2. Nov 13, 20263d ago Insider Cluster Bullish 4/10 Entry $11.49 Now $11.12 −3.22% settles Feb 11
  3. Nov 13, 20263d ago Insider Cluster Bullish 4/10 Entry $11.49 Now $11.12 −3.22% settles Feb 11
  4. Nov 9, 20267d ago 8-K Neutral 5/10 Entry $12.46 Now $11.12 −10.75% settles Feb 8
  5. Aug 24, 202612w ago Insider Cluster Mixed 5/10 Entry $12.50 Now $11.12 −11.04% settles Nov 18
  6. Aug 18, 202612w ago Insider Cluster Bullish 5/10 Entry $11.12 to $11.95 Now $11.12 −0.00% ▲ +7.46% +8.46% vs SPY
  7. Aug 15, 202613w ago Institutional Cluster Bearish 6/10 Entry $11.20 to $12.46 Now $11.12 +0.71% ▼ −11.25% −14.19% vs SPY
  8. Aug 11, 202613w ago 424B5 Bearish 7/10 Viewing Entry $10.36 to $11.13 Now $11.12 −7.39% ▼ −7.48% −12.60% vs SPY
  9. Aug 10, 202614w ago 8-K Bullish 7/10 Entry $9.34 to $12.18 Now $11.12 +19.06% ▲ +30.41% +32.82% vs SPY
  10. Jul 29, 202615w ago 8-K Bullish 6/10 Entry $5.39 to $11.37 Now $11.12 +106.31% ▲ +110.95% +106.22% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens Wed (9h 45m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 11, 2026